Compare PRME & UPBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRME | UPBD |
|---|---|---|
| Founded | 2019 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.0M | 1.1B |
| IPO Year | 2022 | 1996 |
| Metric | PRME | UPBD |
|---|---|---|
| Price | $3.97 | $15.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 6 |
| Target Price | $7.11 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 4.0M | 959.4K |
| Earning Date | 11-06-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 9.94% |
| EPS Growth | ★ 18.18 | N/A |
| EPS | N/A | ★ 0.98 |
| Revenue | $4,632,000.00 | ★ $4,695,061,000.00 |
| Revenue This Year | $90.65 | $0.80 |
| Revenue Next Year | $19.47 | $4.05 |
| P/E Ratio | ★ N/A | $16.01 |
| Revenue Growth | ★ 55.28 | 8.67 |
| 52 Week Low | $2.67 | $14.98 |
| 52 Week High | $6.65 | $23.98 |
| Indicator | PRME | UPBD |
|---|---|---|
| Relative Strength Index (RSI) | 63.75 | 28.89 |
| Support Level | $2.88 | N/A |
| Resistance Level | $4.03 | $16.31 |
| Average True Range (ATR) | 0.34 | 0.55 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 87.96 | 14.17 |
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions, Mexico segment offers lease-to-own stores in Mexico. The The Brigit segment offers various financial health products and tools to help users improve their financial health. The company derives a majority of its revenue from the Acima segment.